Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2019-10-07 AGM Information
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed record of proceedings from the 14th Annual General Meeting (AGM) of a company, including attendance, resolutions passed, appointment and re-appointment of directors, approval of financial statements for the fiscal year ended March 31, 2019, appointment of auditors, and remuneration details. It contains minutes of the meeting with voting results and formal approvals by shareholders. The content is typical of AGM Information, which includes presentations and materials shared during the AGM, rather than a full Annual Report or standalone Audit Report. The document is lengthy (15,000 characters) and contains substantive meeting details, not just an announcement or summary. Therefore, the appropriate classification is AGM Information (AGM-R).
2019-10-07 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed submission of voting results from the 14th Annual General Meeting (AGM) held on 30th September 2019. It includes specifics such as the date of the AGM, number of shareholders present, resolutions passed, and voting percentages. The content focuses on the official results of shareholder votes on various agenda items, including adoption of financial statements and director appointments. There is no indication that this is the full AGM report or presentation, but rather the formal announcement of voting outcomes as required by regulatory compliance. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2019-09-30 English
Trading Window
Regulatory Filings
2019-09-30 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed summary of the proceedings of the 14th Annual General Meeting (AGM) of Beta Drugs Limited held on 30th September 2019. It includes information about the meeting's attendees, the chairman, the resolutions passed, and the voting results. The document references the adoption of financial statements and appointment of directors but does not contain the financial statements themselves or detailed financial data. It is a formal communication to the stock exchange summarizing the AGM proceedings, which fits the definition of AGM Information (AGM-R). The document length is over 11,000 characters, indicating it is not a brief announcement but a full summary of the AGM proceedings.
2019-09-30 English
AGM/Book Closure
AGM Information Classification · 90% confidence The document is very short (226 characters) and contains a table with book closure dates and a reference to the 14th Annual General Meeting of the Company. It appears to be an announcement related to the AGM, specifically about book closure dates for the AGM. There is no detailed report, financial data, or management discussion. This fits best with AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements. Given the brevity and content, confidence is high.
2019-09-03 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed notice convening the 14th Annual General Meeting (AGM) of Beta Drugs Limited, including the agenda items such as adoption of financial statements for the year ended March 31, 2019, appointment and re-appointment of directors, appointment of statutory auditors, remuneration approvals, and other corporate governance matters. The text includes resolutions to be passed at the AGM and details about director appointments and remuneration. It is not the actual annual report or financial statements but the official notice calling the AGM and outlining the business to be transacted. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, such as the notice of meeting and agenda items.
2019-08-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.